- Prior anti-tumor treatment within 14 days before COVID-19 diagnosis is a major risk factor for developing severe events.1
- Patchy consolidation on the first CT on admission is a major risk factor for developing severe events.1
- Patients with blood cancer and metastatic cancer seem to have a higher risk of severe events compared to patients without cancer.2 Patients with non-metastatic cancer do not seem to have a higher risk of severe events compared to patients without cancer.2
- Patient with primary lung metastatic cancer or cancer with metastasis to the lungs are more likely to develop severe anoxia and rapidly worsen.1,2
- Patients who underwent chemotherapy, immunotherapy and surgery seem to have a higher risk of severe events. RT (radiation therapy) and targeted therapy do not seem to increase the risk of severe events.2
This data comes from the analysis of two studies conducted in China. The number of patients with cancer in both studies is small (105 patients for the Dai M.Y et al and 28 patients for Zang L et al.) and therefore information is subject to changes. As new data will emerge, we will make sure to update this page.
- Zhang L., Zhu F., Xie L., Wang C., Chen R., Jia P., Guan H.Q.., Peng L., Chen Y., Peng P., Zhang P., Chu Q., Shen Q., Wang Y., Xu S.Y., Zhao J.P., Zhou M. Ning T., Dengju L., Xiong W., Ziyong S. (March 23, 2020). Clinical characteristics of COVID-19 infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.03.296.
- Dai M.Y., Liu D., Liu M., Zhou F-X., Li G.L., Chen Z., Zhang Z.A., You H., Wu M., Zhen Q.C., Xiong Y., Xiong H.H., Wang C., Chen C.C., Xiong F., Zhang Y., Peng Y.Q., Ge S.P., Zhen B., Yu T.T., Wang L., Wang H., Liu Y., Chen Y.S., Mei J.H., Gao X.J., Li Z.Y., Guan L.H., He C., Li Z., Shi Y.Y., Qi Y.W., Yang J., Tenen D.G., Chai L., Mucci L.A., Santillana M., Cai B.H. On behalf of the Hubei Anti-Cancer Association. (April 08, 2020). Patients with cancer appear more vulnerable to SARS-CoV-2: a multi-center study during the COVID-19 outbreak. The lancet Oncology. http://dx.doi.org/10.2139/ssrn.3558017